TY - JOUR
T1 - Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark
T2 - an observational cohort study
AU - Bager, Peter
AU - Wohlfahrt, Jan
AU - Bhatt, Samir
AU - Stegger, Marc
AU - Legarth, Rebecca
AU - Møller, Camilla Holten
AU - Skov, Robert Leo
AU - Valentiner-Branth, Palle
AU - Voldstedlund, Marianne
AU - Fischer, Thea K.
AU - Simonsen, Lone
AU - Kirkby, Nikolai Søren
AU - Thomsen, Marianne Kragh
AU - Spiess, Katja
AU - Marving, Ellinor
AU - Larsen, Nicolai Balle
AU - Lillebaek, Troels
AU - Ullum, Henrik
AU - Mølbak, Kåre
AU - Krause, Tyra Grove
AU - Edslev, Sofie Marie
AU - Sieber, Raphael Niklaus
AU - Ingham, Anna Cäcilia
AU - Overvad, Maria
AU - Agermose Gram, Mie
AU - Kristensen Lomholt, Frederikke
AU - Hallundbæk, Louise
AU - Hjorth Espensen, Caroline
AU - Gubbels, Sophie
AU - Karakis, Marianne
AU - Lauenborg Møller, Karina
AU - Schytte Olsen, Stefan
AU - Harboe, Zitta Barrella
AU - Klint Johannesen, Caroline
AU - van Wijhe, Maarten
AU - Holler, Jon Gitz
AU - Dessau, Ram Benny Christian
AU - Barfred Friis, Martin
AU - Fuglsang-Damgaard, David
AU - Pinholt, Mette
AU - Vognbjerg Sydenham, Thomas
AU - Coia, John Eugenio
AU - Marmolin, Ea Sofie
AU - Fomsgaard, Anders
AU - Fonager, Jannik
AU - Rasmussen, Morten
AU - Cohen, Arieh
AU - the Omicron-Delta study group
N1 - Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022
Y1 - 2022
N2 - Background: Estimates of the severity of the SARS-CoV-2 omicron variant (B.1.1.529) are crucial to assess the public health impact associated with its rapid global dissemination. We estimated the risk of SARS-CoV-2-related hospitalisations after infection with omicron compared with the delta variant (B.1.617.2) in Denmark, a country with high mRNA vaccination coverage and extensive free-of-charge PCR testing capacity. Methods: In this observational cohort study, we included all RT-PCR-confirmed cases of SARS-CoV-2 infection in Denmark, with samples taken between Nov 21 (date of first omicron-positive sample) and Dec 19, 2021. Individuals were identified in the national COVID-19 surveillance system database, which included results of a variant-specific RT-PCR that detected omicron cases, and data on SARS-CoV-2-related hospitalisations (primary outcome of the study). We calculated the risk ratio (RR) of hospitalisation after infection with omicron compared with delta, overall and stratified by vaccination status, in a Poisson regression model with robust SEs, adjusted a priori for reinfection status, sex, age, region, comorbidities, and time period. Findings: Between Nov 21 and Dec 19, 2021, among the 188 980 individuals with SARS-CoV-2 infection, 38 669 (20·5%) had the omicron variant. SARS-CoV-2-related hospitalisations and omicron cases increased during the study period. Overall, 124 313 (65·8%) of 188 980 individuals were vaccinated, and vaccination was associated with a lower risk of hospitalisation (adjusted RR 0·24, 95% CI 0·22–0·26) compared with cases with no doses or only one dose of vaccine. Compared with delta infection, omicron infection was associated with an adjusted RR of hospitalisation of 0·64 (95% CI 0·56–0·75; 222 [0·6%] of 38 669 omicron cases admitted to hospital vs 2213 [1·5%] of 150 311 delta cases). For a similar comparison by vaccination status, the RR of hospitalisation was 0·57 (0·44–0·75) among cases with no or only one dose of vaccine, 0·71 (0·60–0·86) among those who received two doses, and 0·50 (0·32–0·76) among those who received three doses. Interpretation: We found a significantly lower risk of hospitalisation with omicron infection compared with delta infection among both vaccinated and unvaccinated individuals, suggesting an inherent reduced severity of omicron. Our results could guide modelling of the effect of the ongoing global omicron wave and thus health-care system preparedness. Funding: None.
AB - Background: Estimates of the severity of the SARS-CoV-2 omicron variant (B.1.1.529) are crucial to assess the public health impact associated with its rapid global dissemination. We estimated the risk of SARS-CoV-2-related hospitalisations after infection with omicron compared with the delta variant (B.1.617.2) in Denmark, a country with high mRNA vaccination coverage and extensive free-of-charge PCR testing capacity. Methods: In this observational cohort study, we included all RT-PCR-confirmed cases of SARS-CoV-2 infection in Denmark, with samples taken between Nov 21 (date of first omicron-positive sample) and Dec 19, 2021. Individuals were identified in the national COVID-19 surveillance system database, which included results of a variant-specific RT-PCR that detected omicron cases, and data on SARS-CoV-2-related hospitalisations (primary outcome of the study). We calculated the risk ratio (RR) of hospitalisation after infection with omicron compared with delta, overall and stratified by vaccination status, in a Poisson regression model with robust SEs, adjusted a priori for reinfection status, sex, age, region, comorbidities, and time period. Findings: Between Nov 21 and Dec 19, 2021, among the 188 980 individuals with SARS-CoV-2 infection, 38 669 (20·5%) had the omicron variant. SARS-CoV-2-related hospitalisations and omicron cases increased during the study period. Overall, 124 313 (65·8%) of 188 980 individuals were vaccinated, and vaccination was associated with a lower risk of hospitalisation (adjusted RR 0·24, 95% CI 0·22–0·26) compared with cases with no doses or only one dose of vaccine. Compared with delta infection, omicron infection was associated with an adjusted RR of hospitalisation of 0·64 (95% CI 0·56–0·75; 222 [0·6%] of 38 669 omicron cases admitted to hospital vs 2213 [1·5%] of 150 311 delta cases). For a similar comparison by vaccination status, the RR of hospitalisation was 0·57 (0·44–0·75) among cases with no or only one dose of vaccine, 0·71 (0·60–0·86) among those who received two doses, and 0·50 (0·32–0·76) among those who received three doses. Interpretation: We found a significantly lower risk of hospitalisation with omicron infection compared with delta infection among both vaccinated and unvaccinated individuals, suggesting an inherent reduced severity of omicron. Our results could guide modelling of the effect of the ongoing global omicron wave and thus health-care system preparedness. Funding: None.
U2 - 10.1016/S1473-3099(22)00154-2
DO - 10.1016/S1473-3099(22)00154-2
M3 - Journal article
C2 - 35468331
AN - SCOPUS:85132538661
VL - 22
SP - 967
EP - 976
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
SN - 1473-3099
IS - 7
ER -